Origami Therapeutics / Longevity.Technology · Mar 2026
Interview with CEO Beth Hoffman about using autophagy and protein disposal pathways to target misfolded brain proteins; includes comments on Huntington’s disease and brain healthspan.
Oral drugs to halt neurodegeneration
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Origami Therapeutics, Inc. is a San Diego-based preclinical biotech developing small-molecule protein degraders and protein conformation correctors for neurodegenerative diseases, with a lead focus on Huntington’s disease through its ORICISION™ platform. Public sources conflict on founding year and total funding, so I used the most current company/profile signals and noted the discrepancy in the research.
Primary product
ORICISION™ small-molecule protein degrader/conformation-corrector platform, with lead program ORI-003 for Huntington’s disease
Founded
2016
Headquarters
San Diego, California, United States
Team size
1-10 employees
Industry
Biotechnology Research
Sub-industry
Preclinical neurodegenerative-disease drug discovery / protein degradation therapeutics
Offices
9276 Scranton Rd. Suite 200, San Diego, CA 92121
10210 Campus Point Dr, Suite 150, San Diego, CA 92121
3525 Del Mar Heights Road, Suite 938, San Diego, CA 92130
San Diego, California, United States
Business model
preclinical drug discovery platform
partnered research and licensing
internal pipeline development
Funding
Stage
seed
Total raised
$500K
Latest round
Unattributed VC · Nov 2025
Nov 2025 · NuFund Venture Group
Sep 2022
Mar 2022 · Y Combinator / The Catalytic Impact Foundation
Jan 2016
People & investors
Work & culture
Public recruiting copy describes a collaborative, inclusive, intellectually curious, fast-paced environment, with emphasis on employee training and career development.
Compensation
No public salary bands or equity ranges were disclosed. Public hiring signals only show standard biotech benefits, not compensation details.
Benefits
PTO
holidays
401(k) plan
medical insurance
dental insurance
vision insurance
Product & market
Pricing
Not publicly disclosed; appears to rely on partnership, licensing, and milestone-based collaboration economics.
Differentiators
- —Selective degradation of disease-causing proteins while sparing normal protein forms
- —Combines protein degraders and protein conformation correctors in one platform
- —Uses patient-derived disease models to choose candidates with higher translation potential
- —Small-molecule approach with oral delivery intent
- —Designed for blood-brain-barrier penetration and CNS activity
- —Focuses on previously 'undruggable' protein targets in neurodegenerative disease
Technology
WordPress
PHP
Cloudflare
Competitors
Denali Therapeutics
Fulcrum Therapeutics
Juvenescence
Arvinas
Kymera Therapeutics
Nurix Therapeutics
TRIMTECH Therapeutics
Scale & contact
Estimated revenue
US$1M-$5M (third-party estimates vary; some sources are lower)
Estimated monthly visits
4.3K
Latest news
Origami Therapeutics / Clinical Leader · Mar 2026
Conversation on strategic criteria for rare-disease partnerships and how Origami evaluates collaborators.
San Diego Business Journal · Mar 2026
Reported the Ipsen deal from a local business angle and noted the upfront payment, milestone economics, and Beth Hoffman’s comments on the validation of the platform.
Origami Therapeutics · Jan 2026
Announced a global collaboration and option agreement with Ipsen for a rare inherited neurodegenerative-disease protein degrader program; Ipsen gets an option to license globally after candidate nomination.
Origami Therapeutics · Jun 2025
Origami was named a finalist in BIO International Convention 2025 Start-up Stadium, a useful external validation milestone.
Jobs and careers at Origami Therapeutics, Inc.
0 jobs at Origami Therapeutics, Inc.
No open positions
Check back later for new openings